Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 4/20 | 0.73 |
| ▸ | MAPT | P10636 | 2/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.60 |
| ▸ | TRPV1 | Q8NER1 | 3/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.59 |
| ▸ | FAAH | O00519 | 1/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.56 |
| ▸ | HPGD | P15428 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | GLA | P06280 | 1/20 | 0.54 |
| ▸ | KIF11 | P52732 | 1/20 | 0.54 |
| ▸ | NPC1 | O15118 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 1/20 | 0.54 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL30367847 | 0.98 | EPHX2 (0.71) | EPHX2MAPTKDM4ETRPV1KMT2A | |
| SCHEMBL30140846 | 0.86 | EPHX2 (0.69) | EPHX2MAPTKDM4ETRPV1KMT2A | |
| SCHEMBL16488325 | 0.86 | ALDH1A1 (0.56) | EPHX2MAPTTRPV1KMT2AL3MBTL1 | |
| SCHEMBL9643765 | 0.86 | TRPV1 (0.58) | EPHX2MAPTKDM4ETRPV1KMT2A | |
| SCHEMBL11555827 | 0.85 | EPHX2 (1.00) | EPHX2MAPTTRPV1KMT2AFAAH | |
| SCHEMBL4104599 | 0.84 | EPHX2 (0.61) | EPHX2MAPTKDM4ETRPV1KMT2A | |
| SCHEMBL2096310 | 0.83 | EPHX2 (0.76) | EPHX2MAPTKDM4ETRPV1KMT2A | |
| SCHEMBL2096312 | 0.83 | EPHX2 (0.76) | EPHX2MAPTKDM4ETRPV1KMT2A | |
| SCHEMBL28519915 | 0.83 | EPHX2 (0.65) | EPHX2MAPTKDM4ETRPV1KMT2A | |
| SCHEMBL5643502 | 0.82 | EPHX2 (0.80) | EPHX2MAPTKDM4ETRPV1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 100 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12018021-B2 | Thiophene derivatives for the treatment of disorders caused by IgE | UCB Biopharma SRL (BE) | 2024-06-25 | — | — | US | claimed |
| EP-3810606-A1 | THIOPHENE DERIVATIVES FOR THE TREATMENT OF DISORDERS CAUSED BY IGE | UCB Biopharma SRL (BE) | 2021-04-28 | — | — | EP | claimed |
| WO-2019243550-A1 | THIOPHENE DERIVATIVES FOR THE TREATMENT OF DISORDERS CAUSED BY IGE | UCB Biopharma SRL (BE) | 2019-12-26 | — | — | WO | claimed |
| CN-106928098-B | A kind of synthetic method of indoxacarb intermediate semicarbazone | 江苏优嘉植物保护有限公司 | 2019-02-26 | — | — | CN | claimed |
| CN-106928098-A | A kind of synthetic method of indoxacarb intermediate semicarbazone | 江苏优嘉植物保护有限公司 | 2017-07-07 | — | — | CN | claimed |
| CN-103724293-B | A kind of preparation method of the urea derivative containing 1,2,3-thiadiazoles | 浙江工业大学 | 2016-08-17 | — | — | CN | claimed |
| EP-2611806-A1 | DEUTERIUM-ENRICHED HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS | Ascepion Pharmaceuticals, Inc. (CN) | 2013-07-10 | — | — | EP | claimed |
| WO-2012028106-A1 | DEUTERIUM-ENRICHED HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS | ASCEPION PHARMACEUTICALS, INC. (CN) | 2012-03-08 | — | — | WO | claimed |
| EP-1751113-A1 | UREA ANTAGONISTS OF P2Y1 RECEPTOR USEFUL IN THE TREATMENT OF THROMBOTIC CONDITIONS | Bristol-Myers Squibb Pharma Company (US) | 2007-02-14 | — | — | EP | claimed |
| WO-2005113511-A9 | UREA ANTAGONISTS OF P2Y1 RECEPTOR USEFUL IN THE TREATMENT OF THROMBOTIC CONDITIONS | BRISTOL MYERS SQUIBB CO (US) | 2006-02-02 | — | — | WO | claimed |
| WO-2005113511-A1 | UREA ANTAGONISTS OF P2Y1 RECEPTOR USEFUL IN THE TREATMENT OF THROMBOTIC CONDITIONS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-12-01 | — | — | WO | claimed |
| WO-2002068586-A2 | HIV/FIV PROTEASE INHIBITORS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2002-09-06 | — | — | WO | claimed |
| EP-1005459-A1 | SUBSTITUTED ISOQUINOLINES AS ANTICONVULSIVANTS | SMITHKLINE BEECHAM PLC (GB) | 2000-06-07 | — | — | EP | claimed |
| WO-1999014197-A1 | SUBSTITUTED ISOQUINOLINES AS ANTICONVULSIVANTS | SMITHKLINE BEECHAM PLC (GB) | 1999-03-25 | — | — | WO | claimed |
| US-20260049077-A1 | Neurotrophic Receptor Tyrosine Kinase (NTRK) Inhibitors and Methods Using Same | BAYLOR COLLEGE MEDICINE (US) | 2026-02-19 | — | — | US | disclosed |
| US-20260008768-A1 | UREA DERIVATIVES FOR INHIBITING NLRP3 AND USES THEREOF | VENTUS THERAPEUTICS U S INC (US) | 2026-01-08 | — | — | US | disclosed |
| CN-119707861-A | 2-Substituted aminobenzothiazole compound and application thereof | 沈阳药科大学 | 2025-03-28 | — | — | CN | disclosed |
| WO-2003045937-A1 | N-UREIDO-PIPERIDINES AS ANTAGONISTS VIII FOR CCR-3 RECEPTOR | F. HOFFMANN-LA ROCHE AG (CH) | 2003-06-05 | — | — | WO | disclosed |
| CN-1411448-A | Pyrazole derivatives which modulate human 5-serotonin receptors | ARENA PHARM INC (US) | 2003-04-16 | — | — | CN | disclosed |
| WO-2002068586-A2 | HIV/FIV PROTEASE INHIBITORS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2002-09-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260008768-A1 | UREA DERIVATIVES FOR INHIBITING NLRP3 AND USES THEREOF | NOD1, NLRP3, NOD2 | EPHX2 3161/4885MAPT 585/4885KDM4E 4547/4885 |
| US-12018021-B2 | Thiophene derivatives for the treatment of disorders caused by IgE | TSLP, CYSLTR1, CYSLTR2 | EPHX2 1603/4885MAPT 2356/4885KDM4E 3965/4885 |
| US-20260049077-A1 | Neurotrophic Receptor Tyrosine Kinase (NTRK) Inhibitors and Methods Using Same | NTRK2, NTRK3, NTRK1 | EPHX2 1883/4885MAPT 2742/4885KDM4E 4381/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.